Answers are grounded in this paper and cite their sources.
Background Stenotrophomonas maltophilia is a multidrug-resistant opportunistic pathogen associated with substantial in-hospital mortality. However, data supporting the efficacy of treating S. maltophilia infections using a combination of antimicrobials remain inconclusive. Objectives To assess whether adjunctive minocycline improves clinical outcomes of S. maltophilia infections compared with standard monotherapy. Methods This randomized, double-blind, placebo-controlled trial was conducted at Siriraj Hospital, Thailand. Adults with confirmed S. maltophilia infections were randomized to receive minocycline or a matching placebo in addition to monotherapy with either levofloxacin or trimethoprim/sulfamethoxazole. Results This trial enrolled 112 patients (71.4% [n = 80/112] of patients requiring an intensive care unit [ICU] and 66.1% [n = 74/112] of patients were diagnosed with ventilator-associated pneumonia [VAP]). Baseline demographic and clinical characteristics were balanced between intervention and control groups. Adjunctive minocycline did not significantly reduce 28-day-mortality (n = 24/55[43.6%] vs n = 22/57[38.6%], P = 0.590) but did achieve significantly higher microbiological response rates at early assessment (n = 25/55[45.5%] vs n = 8/57[14.0%], P < 0.001) and the end of treatment (n = 44/55[80.0%] vs n = 32/57[56.1%], P = 0.023). In contrast, clinical response rates did not differ between groups at either 72 h after the start of study treatment or the end of study treatment. In multivariable analysis, two factors were independently associated with 28-day mortality: history of antibiotic use before admission (adjusted odds ratio [aOR]: 7.65, 95% confidence interval [CI]: 2.04–28.76; P = 0.030) and septic shock (aOR: 7.24, 95% CI: 2.75–19.23; P < 0.001). Conclusions Although adding minocycline to either levofloxacin or trimethoprim/sulfamethoxazole therapy enhanced microbiological eradication, it did not confer a measurable survival or clinical advantage. Combination therapy was well tolerated. This study is potentially of interest to those treating ICU patients, as the majority of infections were VAP.
No takes yet. Share an insight, caveat, or question.
Pongdumbun et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: